Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Has Average Target Price of $4.00 According to Analysts

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) has received an average recommendation of “Hold” from the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $4.00.

HOWL has been the topic of a number of recent analyst reports. Wall Street Zen upgraded Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 22nd. Weiss Ratings raised shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th.

Werewolf Therapeutics Price Performance

NASDAQ HOWL opened at $0.93 on Wednesday. The business has a fifty day moving average price of $0.75 and a two-hundred day moving average price of $0.64. The stock has a market capitalization of $45.11 million, a PE ratio of -1.22 and a beta of 0.51. Werewolf Therapeutics has a fifty-two week low of $0.27 and a fifty-two week high of $2.15.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings results on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.36. The business had revenue of $21.00 million during the quarter, compared to the consensus estimate of $21.00 million. As a group, sell-side analysts expect that Werewolf Therapeutics will post -0.89 earnings per share for the current year.

Insider Activity

In related news, Director Luke Evnin sold 107,429 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $0.31, for a total transaction of $33,302.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 23.60% of the company’s stock.

Institutional Trading of Werewolf Therapeutics

A number of hedge funds have recently added to or reduced their stakes in HOWL. BlackRock Inc. bought a new stake in shares of Werewolf Therapeutics during the second quarter worth $37,000. Squarepoint Ops LLC bought a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at $37,000. Finally, Bank of America Corp DE bought a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at $112,000. Institutional investors and hedge funds own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies. The company uses its proprietary INDUKINE platform to design conditionally activated cytokines, which are intended to stimulate the immune system within the tumor microenvironment while limiting activity in healthy tissues.

Werewolf’s pipeline has included WTX-124, an investigational interleukin-2 therapy designed to promote the expansion and activation of immune cells in tumors, and WTX-330, an investigational interleukin-12 therapy intended to activate both innate and adaptive immune responses.